Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Dual Inhibition of EGFR and VEGF in Heavily Pretreated Patients with Metastatic Colorectal Cancer

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

APA

CBE

MLA

Vancouver

Author

Bibtex

@article{7a18a21ec14e4e32b1451d6ffb860cd1,
title = "Dual Inhibition of EGFR and VEGF in Heavily Pretreated Patients with Metastatic Colorectal Cancer",
abstract = "OBJECTIVE: The aim of this study was to evaluate the efficacy and safety of combining irinotecan, bevacizumab, and cetuximab/panitumumab as a 4th-line treatment in patients with metastatic colorectal cancer.METHODS: All patients had KRAS wild-type metastatic colorectal cancer and had previously received fluoropyrimidine, oxaliplatin, irinotecan, and cetuximab/panitumumab in a 1st, 2nd, and 3rd line setting. Most patients had previously received bevacizumab as well. All patients had progressed within 3 months after the last given treatment before starting the triple combination therapy every second week.RESULTS: Sixty-three patients were evaluated. The triple combination therapy was well tolerated. The median progression-free survival was 6.1 months, and the median overall survival was 11.9 months. Four patients (6{\%}) obtained a partial response, and 40 (63{\%}) had stable disease.CONCLUSION: The combination of irinotecan, bevacizumab, and cetuximab/panitumumab is safe and shows a toxicity profile corresponding to what is expected from the agents alone. The results indicate that the combination in the 4th line may result in a high rate of disease control in heavily pretreated patients with metastatic colorectal cancer.",
keywords = "Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols, Bevacizumab, Camptothecin, Cetuximab, Colorectal Neoplasms, Disease-Free Survival, Drug Administration Schedule, Female, Fluorouracil, Humans, Male, Middle Aged, Organoplatinum Compounds, Receptor, Epidermal Growth Factor, Retrospective Studies, Survival Rate, Treatment Outcome, Vascular Endothelial Growth Factor A, Journal Article",
author = "Larsen, {Finn Ole} and Alice Markussen and Dorte Nielsen and Bonnie Colville-Ebeling and Riis, {Lene B} and Jensen, {Benny V}",
note = "{\circledC} 2017 S. Karger AG, Basel.",
year = "2017",
doi = "10.1159/000475818",
language = "English",
volume = "93",
pages = "191--196",
journal = "Oncology",
issn = "0030-2414",
publisher = "S./Karger AG",
number = "3",

}

RIS

TY - JOUR

T1 - Dual Inhibition of EGFR and VEGF in Heavily Pretreated Patients with Metastatic Colorectal Cancer

AU - Larsen, Finn Ole

AU - Markussen, Alice

AU - Nielsen, Dorte

AU - Colville-Ebeling, Bonnie

AU - Riis, Lene B

AU - Jensen, Benny V

N1 - © 2017 S. Karger AG, Basel.

PY - 2017

Y1 - 2017

N2 - OBJECTIVE: The aim of this study was to evaluate the efficacy and safety of combining irinotecan, bevacizumab, and cetuximab/panitumumab as a 4th-line treatment in patients with metastatic colorectal cancer.METHODS: All patients had KRAS wild-type metastatic colorectal cancer and had previously received fluoropyrimidine, oxaliplatin, irinotecan, and cetuximab/panitumumab in a 1st, 2nd, and 3rd line setting. Most patients had previously received bevacizumab as well. All patients had progressed within 3 months after the last given treatment before starting the triple combination therapy every second week.RESULTS: Sixty-three patients were evaluated. The triple combination therapy was well tolerated. The median progression-free survival was 6.1 months, and the median overall survival was 11.9 months. Four patients (6%) obtained a partial response, and 40 (63%) had stable disease.CONCLUSION: The combination of irinotecan, bevacizumab, and cetuximab/panitumumab is safe and shows a toxicity profile corresponding to what is expected from the agents alone. The results indicate that the combination in the 4th line may result in a high rate of disease control in heavily pretreated patients with metastatic colorectal cancer.

AB - OBJECTIVE: The aim of this study was to evaluate the efficacy and safety of combining irinotecan, bevacizumab, and cetuximab/panitumumab as a 4th-line treatment in patients with metastatic colorectal cancer.METHODS: All patients had KRAS wild-type metastatic colorectal cancer and had previously received fluoropyrimidine, oxaliplatin, irinotecan, and cetuximab/panitumumab in a 1st, 2nd, and 3rd line setting. Most patients had previously received bevacizumab as well. All patients had progressed within 3 months after the last given treatment before starting the triple combination therapy every second week.RESULTS: Sixty-three patients were evaluated. The triple combination therapy was well tolerated. The median progression-free survival was 6.1 months, and the median overall survival was 11.9 months. Four patients (6%) obtained a partial response, and 40 (63%) had stable disease.CONCLUSION: The combination of irinotecan, bevacizumab, and cetuximab/panitumumab is safe and shows a toxicity profile corresponding to what is expected from the agents alone. The results indicate that the combination in the 4th line may result in a high rate of disease control in heavily pretreated patients with metastatic colorectal cancer.

KW - Adult

KW - Aged

KW - Aged, 80 and over

KW - Antibodies, Monoclonal

KW - Antibodies, Monoclonal, Humanized

KW - Antineoplastic Combined Chemotherapy Protocols

KW - Bevacizumab

KW - Camptothecin

KW - Cetuximab

KW - Colorectal Neoplasms

KW - Disease-Free Survival

KW - Drug Administration Schedule

KW - Female

KW - Fluorouracil

KW - Humans

KW - Male

KW - Middle Aged

KW - Organoplatinum Compounds

KW - Receptor, Epidermal Growth Factor

KW - Retrospective Studies

KW - Survival Rate

KW - Treatment Outcome

KW - Vascular Endothelial Growth Factor A

KW - Journal Article

U2 - 10.1159/000475818

DO - 10.1159/000475818

M3 - Journal article

VL - 93

SP - 191

EP - 196

JO - Oncology

JF - Oncology

SN - 0030-2414

IS - 3

ER -

ID: 52652178